Spots Global Cancer Trial Database for lymphoproliferative disorders
Every month we try and update this database with for lymphoproliferative disorders cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) | NCT03099031 | Venous Thromboe... | Tinzaparin | 18 Years - | LEO Pharma | |
| An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas | NCT05011058 | Epstein-Barr Vi... EBV-Related PTL... EBV Related Non... EBV-Positive DL... EBV Associated ... EBV Related PTC... | Nanatinostat in... | 18 Years - | Viracta Therapeutics, Inc. | |
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | NCT05804032 | Multiple Myelom... | Isatuximab Isatuximab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients | NCT01420679 | Peripheral T-ce... | Pralatrexate In... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy | NCT01101399 | Iron-Deficiency... | Ferric carboxym... | 18 Years - | Vifor Pharma | |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT03373019 | Chidamide Lymphoma, B-Cel... Lymphoma, Large... Neoplasm by His... Neoplasms Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... Lymphoma, Non-H... Cyclophosphamid... Rituximab Gemcitabine Cisplatin Dexamethasone HDAC Inhibitor | Chidamide combi... | 18 Years - 75 Years | Fudan University | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Study of the BiTEĀ® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | NCT01209286 | B-ALL | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| Virtual Rehabilitation for Cancer Survivors | NCT05898789 | Breast Cancer, ... Colorectal Canc... Head and Neck C... Lymphoma Breast Cancer S... Breast Cancer S... Breast Cancer S... Colorectal Canc... Colorectal Canc... Head and Neck C... Head and Neck C... Lymphoprolifera... | CaRE@Home inter... | 18 Years - | University Health Network, Toronto | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | NCT04529772 | Diffuse Large B... | acalabrutinib placebo Prednisone Rituximab Cyclophosphamid... Vincristine Doxorubicin | 18 Years - 75 Years | Acerta Pharma BV | |
| In Vitro Drug Sensitivity Testing of Fresh Human Samples | NCT05001386 | Myeloproliferat... Lymphoprolifera... | Blood collectio... | 18 Years - | Hospices Civils de Lyon | |
| Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | NCT01471782 | Acute Lymphobla... | Blinatumomab | - 17 Years | Amgen Research (Munich) GmbH | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | NCT04858256 | T-Cell Neoplasm Lymphoprolifera... | Pacritinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT01466179 | Acute Lymphobla... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma | NCT00435916 | Lymphoma, Large... Lymphoma, Non-H... | SGN-40 | 18 Years - | Seagen Inc. | |
| Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders | NCT00992732 | Lymphoid Malign... Lymphoprolifera... | HQK-1004 Valganciclovir ... | 3 Years - | HemaQuest Pharmaceuticals Inc. | |
| Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | NCT00655837 | Lymphoma, Large... Lymphoma, Non-H... | SGN-40 rituximab gemcitabine | 18 Years - | Seagen Inc. | |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia | NCT02733042 | Lymphoma Leukemia, Lymph... | Durvalumab Lenalidomide Rituximab Ibrutinib Bendamustine | 18 Years - | Celgene | |
| A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | NCT04104776 | Advanced Solid ... Diffuse Large B... Lymphoma, T-Cel... Mesothelioma, M... Prostatic Neopl... Endometrial Can... Ovarian Clear C... | CPI-0209 | 18 Years - | Constellation Pharmaceuticals | |
| Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy | NCT01435356 | Urinary Bladder... | recMAGE-A3 + AS... Placebo | 18 Years - | European Association of Urology Research Foundation | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | NCT03601819 | Lymphoma, T-Cel... Lymphoma, T-Cel... Chronic Lymphoc... Lymphoprolifera... Waldenstrom Mac... Lymphoplasmacyt... Mantle Cell Lym... | Pacritinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy | NCT01101399 | Iron-Deficiency... | Ferric carboxym... | 18 Years - | Vifor Pharma | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| A Safety Study in Patients With Chronic Lymphocytic Leukemia | NCT00283101 | Leukemia, Lymph... | SGN-40 (anti-hu... | 18 Years - | Seagen Inc. | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT01741792 | Diffuse Large B... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| A Safety Study in Patients With Chronic Lymphocytic Leukemia | NCT00283101 | Leukemia, Lymph... | SGN-40 (anti-hu... | 18 Years - | Seagen Inc. | |
| Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | NCT00048412 | Myelodysplastic... Leukemia Multiple Myelom... Plasma Cell Dys... Lymphoprolifera... | FLUDARABINE CAMPATH 1H FK50 Stem Cell Colle... | - 70 Years | Baylor College of Medicine | |
| Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies | NCT03397706 | Epstein-Barr Vi... Lymphoprolifera... | VRx-3996 Valganciclovir | 18 Years - | Viracta Therapeutics, Inc. | |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | NCT01183949 | Multiple Myelom... | AT7519M Bortezomib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients | NCT01420679 | Peripheral T-ce... | Pralatrexate In... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy | NCT03394365 | Epstein-Barr Vi... Solid Organ Tra... Lymphoprolifera... Allogeneic Hema... Stem Cell Trans... | tabelecleucel | - | Atara Biotherapeutics | |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | NCT00701844 | Leukemia Acute Leukemia Acute Lymphocyt... Multiple Myelom... Hematological C... Psychological D... | Writing A (Expe... Writing B (Expe... Writing C (Cont... Writing D (Cont... | 18 Years - | University of North Carolina, Chapel Hill | |
| Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) | NCT02657447 | Non-Hodgkin Lym... | Betalutin with ... Betalutin with ... | 18 Years - | Nordic Nanovector | |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | NCT00701844 | Leukemia Acute Leukemia Acute Lymphocyt... Multiple Myelom... Hematological C... Psychological D... | Writing A (Expe... Writing B (Expe... Writing C (Cont... Writing D (Cont... | 18 Years - | University of North Carolina, Chapel Hill | |
| A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT05431179 | Lymphoma, Mantl... Lymphoma Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... Lymphoma, Non-H... Lymphoma, B-Cel... | Zilovertamab Ibrutinib Placebo | 18 Years - | Oncternal Therapeutics, Inc | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | NCT05155215 | Lymphoma Lymphoma, Mantl... Neoplasms by Hi... Neoplasms Lymphoprolifera... | IM19 CAR-T cell... Cyclophosphamid... Fludarabine | 18 Years - | Beijing Immunochina Medical Science & Technology Co., Ltd. | |
| A Study of Patients With AIDS Syndrome | NCT00001120 | Sarcoma, Kaposi Lymphoma, Non-H... HIV Infections Lymphoma, AIDS-... | 18 Years - | National Institute of Allergy and Infectious Diseases (NIAID) | ||
| Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | NCT02973113 | NonHodgkin Lymp... Lymphoprolifera... EBV Related Lym... EBV-Related PTL... Hodgkin Lymphom... EBV Related Non... EBV Related Hod... | EBVST Cells Nivolumab | - | Baylor College of Medicine | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| A Safety Study in Patients With Chronic Lymphocytic Leukemia | NCT00283101 | Leukemia, Lymph... | SGN-40 (anti-hu... | 18 Years - | Seagen Inc. | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | NCT02690545 | Lymphoma Lymphoma, Non-H... Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Neoplasms by Hi... | ATLCAR.CD30 cel... | 3 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | NCT04529772 | Diffuse Large B... | acalabrutinib placebo Prednisone Rituximab Cyclophosphamid... Vincristine Doxorubicin | 18 Years - 75 Years | Acerta Pharma BV | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | NCT00773747 | Multiple Myelom... | Vorinostat bortezomib placebo to vori... | 18 Years - | Merck Sharp & Dohme LLC | |
| An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas | NCT05011058 | Epstein-Barr Vi... EBV-Related PTL... EBV Related Non... EBV-Positive DL... EBV Associated ... EBV Related PTC... | Nanatinostat in... | 18 Years - | Viracta Therapeutics, Inc. | |
| Study of INCB053914 in Subjects With Advanced Malignancies | NCT02587598 | Solid Tumors | INCB053914 I-DAC (Intermed... Azacitidine Ruxolitinib | 18 Years - | Incyte Corporation | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| Lymphoma Epidemiology of Outcomes Cohort Years 6-10 | NCT04996706 | Lymphoma, Non-H... | 18 Years - | Mayo Clinic | ||
| Lymphoproliferative Disorders After Diagnosis of Childhood Acute Lymphoblastic Leukemia/Lymphoma | NCT04055558 | Childhood Leuke... | - 30 Years | Rabin Medical Center | ||
| Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia | NCT00117845 | Leukemia, Adult... | Denileukin dift... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | NCT00113802 | Waldenstrom Mac... | Epratuzumab (hL... | 18 Years - | Gilead Sciences | |
| SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | NCT00365274 | Anaplastic Larg... | Cyclophosphamid... Doxorubicin hyd... vincristine sul... prednisone SGN-30 | 18 Years - | National Cancer Institute (NCI) | |
| Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | NCT00579111 | Myelodysplastic... Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Multiple Myelom... Plasma Cell Dys... Lymphoprolifera... Hematologic Dis... | Campath Busulfan Fludarabine Hematopoietic s... FK-506 | - 70 Years | Baylor College of Medicine | |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | NCT03744676 | Lymphoma, Non-H... Lymphoma Lymphoma, B-Cel... Lymphoma, Large... Neoplasms Neoplasms by Hi... Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... | lisocabtagene m... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy | NCT03394365 | Epstein-Barr Vi... Solid Organ Tra... Lymphoprolifera... Allogeneic Hema... Stem Cell Trans... | tabelecleucel | - | Atara Biotherapeutics | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy | NCT01100879 | Iron-Deficiency... | Ferric carboxym... | 18 Years - | Vifor Pharma | |
| Study of the BiTEĀ® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | NCT01209286 | B-ALL | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs). | NCT00058604 | Epstein-Barr Vi... Lymphoprolifera... | Intravenous inj... | - 70 Years | Baylor College of Medicine | |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | NCT04904588 | Acute Lymphobla... Acute Myelogeno... Mixed Phenotype... Acute Leukemia Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Lymphoma | Busulfan Busulfan Fludarabine Total-body irra... Cyclophosphamid... Melphalan PBSC Hematopoie... Bone Marrow Hem... Post-transplant... Mesna Tacrolimus Mycophenolate M... Patient-Reporte... | 1 Year - | Center for International Blood and Marrow Transplant Research | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| In Vitro Drug Sensitivity Testing of Fresh Human Samples | NCT05001386 | Myeloproliferat... Lymphoprolifera... | Blood collectio... | 18 Years - | Hospices Civils de Lyon | |
| Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | NCT02973113 | NonHodgkin Lymp... Lymphoprolifera... EBV Related Lym... EBV-Related PTL... Hodgkin Lymphom... EBV Related Non... EBV Related Hod... | EBVST Cells Nivolumab | - | Baylor College of Medicine | |
| Pathogenesis of Hematologic Malignancies | NCT01728402 | Acute Leukemia Lymphoprolifera... Myeloproliferat... Myelodysplastic... | blood draw, bon... | 1 Year - | OHSU Knight Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
